Trial record 1 of 1 for:
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients (THERAVAC)
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2012 by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.
Recruitment status was: Recruiting
Information provided by (Responsible Party):
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
First received: January 20, 2011
Last updated: October 8, 2012
Last verified: October 2012
In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.
The primary objective is to analyze the safety of the inreasing doses of vaccine.
The secondary objective is to document whether this vaccine can induce tumor regression in immunized patients.
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.
Primary Outcome Measures:
- To analyze the safety and toxicity of increasing doses of Theravac® in patients with advanced metastatic melanoma [ Time Frame: the first 3 months of treatment ] [ Designated as safety issue: Yes ]
The toxicity will be assess after the treatment (3 months) for the first three patients of each group.
- To determine whether these immunizations result in a detectable immune response [ Time Frame: Up to 24 weeks ] [ Designated as safety issue: No ]
PBMC will be obtained from the buffy-coat of 500 ml of venous blood or from 100 ml of venous blood collected before and after immunization.
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||October 2013 (Final data collection date for primary outcome measure)
Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.
Injection: intradermally and subcutaneously.
There are three treatment cohorts and the inclusion of patients in governed by the dose-limiting toxicities in the previous cohort.
- the first three patients will receive a dose of 50 µg of Theravac®
- second cohort of three patients will receive a dose of 150 µg Theravac®
- the third cohort of three patients will receive a dose of 250 µg Theravac® and eventually a total of 14 patients will complete the step with the highest dose.
All the patients will receive four immunizations every three weeks in two intradermal sites and in two subcutaneous sites.
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Histologically proven cutaneous, uveal or mucosal melanoma.
- Melanoma must be metastatic. The origin of the primary could be cutaneous, uveal or mucosal and any metastatic stage is accepted, except if brain or leptomeningeal localizations are present, or if plasma LDH are elevated more than 1.5 normal upper values (see also below).
- HLA-A2 positive.
- The melanoma must express the tyrosinase gene (positive RT-PCR on a frozen pre-immune tumor sample) (see Appendix B).
- At least one measurable or non-measurable tumor lesion (see Section 8.1).
- Expected survival of at least 3 months.
- Karnofsky performance scale ≥70 or WHO performance status of 0 or 1 (see Appendix C).
Vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:
Lab Parameter Range Hemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l Granulocytes ≥ 1,500/µl Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Serum creatinin ≤ 2.0 mg/dl or ≤ 177 μmol/l Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 μmol/l ASAT and ALAT ≤ 2 x the normal upper limits LDH ≤ 1.5 x the normal upper limit.
- HIV (human immunodeficiency virus): negative antibodies.
- HBV (hepatitis B virus): negative antigens; antibodies may be positive.
- HCV (hepatitis C virus): negative antibodies.
- Age ≥ 18 years
- Able and willing to give valid written informed consent
- Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).
- Previous treatment with a vaccine known or likely to contain the Tyrosinase.A2 epitope YMDGTMSQV.
- Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.
- Active immunodeficiency or autoimmune disease. Vitiligo is not an exclusion criterion.
- Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.
- Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.
- Allergy to kanamycin (used in the preparation of the recombinant protein) or to any other aminoglycoside antibiotic.
- Lack of availability for immunological and clinical follow-up assessments.
- Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
- Pregnancy or breastfeeding.
- Women of childbearing potential: Refusal or inability to use effective means of contraception.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01331915
|Cliniques universitaires Saint-Luc, Centre du Cancer
|Brussels, Belgium, 1200 |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
||Jean-François Baurain, MD, PhD
||Cliniques universitaires Saint-Luc, Centre du Cancer
||Cliniques universitaires Saint-Luc- Université Catholique de Louvain
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 20, 2011
||October 8, 2012
||Belgium: Federal Agency for Medicinal Products and Health Products
Keywords provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain:
Tyrosinase.A2 gene expression
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 02, 2016
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas